Increased epilepsy risk identified in multiple sclerosis

Increased epilepsy risk identified in multiple sclerosis

A direct correlation exists between the presence and severity of multiple sclerosis (MS) and the risk for epilepsy, according to study findings published in Neurology.

Investigators obtained patient data from the Swedish MS register (n=14,545) and compared these patients with 43,635 age- and sex-matched controls from the patient register.

Overall, the cumulative epilepsy incidence was 3.5% (95% confidence interval [CI] 3.17-3.76) in patients with MS vs 1.4% (95% CI, 1.30-1.52) in controls (risk ratio 2.5, 95% CI 2.19-2.76). The investigators found an increased risk for epilepsy in patients with MS compared with controls in a Cox proportional model (hazard ratio 3.2; 95% CI, 2.64-3.94). Progressive MS was associated with a higher cumulative incidence of epilepsy compared with relapsing-remitting MS (5.5% [95% CI, 4.89-6.09] vs 2.2% [95% CI, 1.88-2.50], respectively).

Patients with a longer MS disease duration also demonstrated greater cumulative epilepsy incidence. A 5.9% (95% CI, 4.90-7.20) cumulative incidence was observed in patients with an MS duration of 34 years or longer. Following a multiple logistic regression analysis, an Expanded Disability Status Scale (EDSS) score ≥7 and greater disease duration were found to correlate with a greater incidence of epilepsy (odds ratio [OR] 1.03; 95% CI, 1.01-1.04 per year,  P =.001; and OR 1.2; 95% CI, 1.09-1.26 per Expanded Disability Status Scale [EDSS]step, P <.0001).

It is possible that the researchers had underestimated epilepsy prevalence in this cohort. In addition, the reliance on ICD codes for detecting epilepsy may have led to incorrect disease identification in some cases, considering the questionable validity of ICD codes for establishing an epilepsy diagnosis.

The finding that MS disease duration is associated with a higher risk for epilepsy “raises the possibility that mechanisms in addition to cortical lesion load, eg, long-standing neuroinflammation, could influence the risk of epilepsy.”

Reference

Burman J, Zelano J. Epilepsy in multiple sclerosis: A nationwide population-based register study. Neurology [published online November 8, 2017]. doi:10.1212/WNL.0000000000004740

By Brandon May

Neurology Advisor

CMSC Disclaimer

The industry news information and articles are for informational purposes only, and are not intended to represent any trends, partnerships, commitments, or research of the Consortium of MS Centers or any of it's members in any way whatsoever, nor should any party be libel in any way to the reader or to any other person, firm or corporation reading this industry news section. Although the CMSC site includes links providing direct access to other Internet sites, CMSC takes no responsibility for the content or information contained on those other sites, and does not exert any editorial or other control over those other sites. CMSC is providing information and services on the Internet as a benefit and service in furtherance of CMSC's nonprofit and tax-exempt status. CMSC makes no representations about the suitability of this information and these services for any purpose.

Elizabeth Porco

Comments are closed.

  • (201) 487-1050
  • 3 University Plz Dr Ste 116, Hackensack, NJ 07601
  • info@mscare.org

Upcoming Testing Periods

WINTER 2024 TESTING PERIOD

Application Deadline: December 6th, 2023

First Day of Testing: Saturday, January 6th, 2024

Last Day of Testing: Saturday, January 20th, 2024

SUMMER 2024 TESTING PERIOD

Application Deadline: May 1st, 2024

First Day of Testing: Saturday, June 1st, 2024

Last Day of Testing: Saturday, June 15th, 2024

Resources

Visit PTC to download a PDF version of the Handbook. Candidates can also apply online.

For more information:

Professional Testing Corporation http://www.ptcny.com/

  • 212-356-0660
  • 1350 Broadway, 17th Floor, New York, NY 10018

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us





I have a question about

First

Last




Feel Free To contact Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam molestie, tellus id pellen tesque feugiat, sem sem cursus orci, a placerat ante ante nec massa. consectetuer adipiscing elit.

+1-222-333-4444

New York, NY 10123 USA

Mon - Sat 9:00 AM